Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC

Summary

This is a prospective, single-arm, exploratory clinical study enrolling patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma (ESCC) confirmed by histology or cytology. The study aims to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab in combination with famitinib and chemotherapy in this population. The primary endpoint is the pathological complete response (pCR) rate, with a planned enrollment of 24 patients.

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Adebrelimab + Famitinib + Chemotherapy

Adebrelimab 1200 mg will be administered intravenously on Day 1 of each 3-week cycle (Q3W). Paclitaxel 175 mg/m² and cisplatin 75 mg/m² will also be administered intravenously on Day 1 (Q3W). Drugs will be infused in the following order with at least a 30-minute interval: Adebrelimab → Paclitaxel → Cisplatin. Famitinib 10 mg will be taken orally once daily (po, qd), 30 minutes after a meal, for 2 weeks on treatment followed by 1 week off (Q3W). A total of 2 treatment cycles will be administered before surgery.

Sponsors & Collaborators

• First Affiliated Hospital Xi'an Jiaotong University

  lead OTHER

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-10-30

Primary Completion

2028-10-30

Completion

2028-10-30

Countries

• China

Study Locations